Form 8-K

8-K — DYADIC INTERNATIONAL INC

Accession: 0001493152-26-025554

Filed: 2026-05-28

Period: 2026-05-28

CIK: 0001213809

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (form8-k_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001213809

2026-05-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (date of earliest event reported): May 28,

2026

Dyadic

International, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-32513

45-0486747

(State

or other jurisdiction

incorporation or organization)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

1044

North U.S. Highway One, Suite

201

Jupiter,

FL 33477

(Address

of principal executive offices and zip code)

(561)

743-8333

(Registrant’s

telephone number, including area code)

N/A

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

DYAI

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

May 28, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) issued a press release titled “Dyadic

and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development: Collaboration Leverages Prior Andes,

Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic Production”. The press

release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The

information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall

not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any

filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference

in such a filing.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits:

Exhibit

Number

Description

99.1

Dyadic International, Inc. Press Release Dated May 28, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

May 28, 2026

Dyadic

International, Inc.

By:

/s/

Ping Rawson

Name:

Ping

Rawson

Title:

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Dyadic

and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Collaboration

Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic Production

JUPITER,

Fla., May 28, 2026 — Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,”

or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and

commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical

applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal

antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary

Syndrome (HPS), a severe and potentially fatal respiratory disease in humans.

series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic preparedness and highlighted

the need to improve the speed, scalability, flexibility, and cost-effectiveness of biologic manufacturing during rapidly evolving public

health events. The collaboration builds upon Dyadic’s prior Andes virus monoclonal antibody work and combines the complementary

expertise of Dyadic and Scripps Research to further assess the potential of Dyadic’s proprietary C1 platform for rapid development

timelines, high-productivity microbial fermentation, large-scale manufacturing, and biologic production intended to support future infectious

disease preparedness.

Dyadic’s

microbial fungal-based C1 platform has been applied to multiple biologic modalities, including recombinant vaccine antigens and monoclonal

antibodies targeting RSV, malaria, the Andes virus, Ebola, and Marburg, which is similar to Ebola and comes from the same family of viruses—the

Filovirus family, and has demonstrated in preclinical studies the ability to produce monoclonal antibodies with binding, neutralization,

and efficacy characteristics comparable to those generated by traditional mammalian expression systems.

prior Andes virus-related work, Dyadic developed a C1 strain expressing the recombinant anti-Andes virus monoclonal antibody rANDV-44,

where, Dyadic believes, the data generated demonstrated virus neutralization activity comparable to ExpiCHO-produced material in a pseudovirus

neutralization assay.

Dyadic

has also previously demonstrated GMP-compliant manufacturing and Phase 1 clinical evaluation of biologics produced using its C1 platform

as part of earlier infectious disease initiatives. The Company is currently involved in multiple funded biopharmaceutical collaborations,

including programs supported by the Gates Foundation and the Coalition for Epidemic Preparedness Innovations (“CEPI”) in

collaboration with Fondazione Biotecnopolo di Siena (“FBS”), aimed at accelerating recombinant protein vaccines and monoclonal

antibody development workflows using the C1 platform.

Dyadic’s

C1 platform was previously included in the European Union-supported Zoonosis Anticipation and Preparedness Initiative (“ZAPI”),

a five-year pandemic preparedness program involving leading global human and animal health organizations focused on accelerating biologic

manufacturing technologies for emerging infectious diseases. Building upon the progress achieved from ZAPI, Dyadic’s more recent

and ongoing funded collaborations supported by the Gates Foundation, CEPI, FBS, and activities associated with the EU Vaccine Hub continue

to advance rapid, scalable biologic manufacturing approaches using the C1 platform to help address many of the manufacturing bottlenecks

revealed during COVID-19 and other emerging infectious disease outbreaks.

Together,

these programs continue to generate data that support the potential advantages of the C1 platform, including compressed development timelines,

scalable microbial fermentation, and streamlined manufacturing processes. Additional studies have shown that C1-produced monoclonal antibodies

can achieve binding and neutralization properties comparable to antibodies produced in traditional mammalian systems.

“One

of the key lessons from recent global outbreaks is that scientific innovation alone is not sufficient — manufacturing flexibility,

scale and speed are also critical,” said Jiang Zhu, Professor at Scripps Research. “Collaborations that bring together advanced

antibody and antigen research with rapid biologic production technologies may help strengthen preparedness for future infectious disease

threats.”

Dr.

Zhu continued, “My laboratory at Scripps Research has developed proprietary structure-based protein designs optimized for conformational

integrity, trimer closure, and antigen quality. In parallel, innovative expression technologies such as Dyadic’s C1 platform may

offer opportunities to further evaluate faster, more scalable and potentially lower-cost approaches for the development and manufacture

of complex biologics targeting emerging infectious diseases.”

“COVID-19

demonstrated that manufacturing scalability and deployment speed remain critical challenges during global outbreaks,” said Mark

Emalfarb, Dyadic’s Chief Executive Officer. “Our collaboration with Scripps builds upon prior hantavirus-related work and

reflects our broader strategy of partnering with leading research institutions and global health organizations to evaluate how we anticipate

the C1 platform will contribute to future pandemic preparedness initiatives.”

Mr.

Emalfarb continued, “Importantly, these activities continue to be pursued through grants, sponsored research, and strategic collaborations,

allowing Dyadic to further validate the C1 platform in a capital-efficient manner while maintaining our primary commercial focus on non-pharmaceutical

protein products and industrial-scale biomanufacturing opportunities.”

Dyadic

and Scripps plan to jointly explore external partnership and non-dilutive funding opportunities to support additional development activities

related to monoclonal antibodies, and vaccine candidates, and broader infectious disease preparedness applications.

Dyadic

recently highlighted growing commercial activity with recombinant proteins and enzymes in non-pharmaceutical applications, including

animal-free proteins for life sciences, cell culture media, nutrition, wellness, and industrial markets.

About

Dyadic Applied BioSolutions

Dyadic

Applied BioSolutions is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production

platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins

are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s proprietary Dapibus™

and C1 expression systems support rapid, cost-effective, and flexible manufacturing.

For

more information, please visit http://www.dyadic.com.

Safe

Harbor Regarding Forward-Looking Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange

Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events

or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research

projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be

identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,”

“project,” “may,” “might,” “potential,” or “continue” and other similar terms

or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking

information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking

information. Such statements reflect the current views of our management with respect to our operations, results of operations and future

financial performance. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic’s control.

These factors include, but are not limited to (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein

production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies;

(iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital

needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence

on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; (xii)

our ability to comply with the listing standards of the Nasdaq Stock Market LLC; and (xii) other factors discussed in Dyadic’s

publicly available filings, including information set forth under the caption “Risk Factors” in Dyadic’s annual report

on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, as amended on April 30, 2026, and

quarterly report on Form 10-Q filed with the SEC on May 13, 2026, as such factors may be updated from time to time in Dyadic’s

periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. The forward-looking statements

contained in this press release are made only as of the date hereof, and except as required by law, we undertake no obligation to publicly

update any forward-looking statements for any reason after the date of this press release to conform these statements to actual results

or to changes in our expectations.

Media

contacts:

Dyadic

Applied BioSolutions:

Ping

Rawson

Chief

Financial Officer

Phone:

(561) 743-8333

Email:

ir@dyadic.com

GRAPHIC

Filename: form8-k_001.jpg · Sequence: 3

Binary file (4396 bytes)

Download form8-k_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 28, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 28, 2026

Entity File Number

001-32513

Entity Registrant Name

Dyadic

International, Inc.

Entity Central Index Key

0001213809

Entity Tax Identification Number

45-0486747

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1044

North U.S. Highway One

Entity Address, Address Line Two

Suite

201

Entity Address, City or Town

Jupiter

Entity Address, State or Province

Entity Address, Postal Zip Code

33477

City Area Code

(561)

Local Phone Number

743-8333

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

DYAI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration